Prevalence Study of Iron Deficiency in Patients With Cancer

VIFORFRANCE1,200 enrolled

Overview

Despite its high prevalence, a recent study conducted by Prof. Cacoub (unpublished) on the french national health insurance database showed that iron deficiency was an underdiagnosed and under-treated co-morbidity. In inflammatory situations, especially during cancer, the measurement of the transferrin saturation factor is only performed in about 10% of cases whereas this measure is recommended in inflammatory situations including cancer (French Health High Authority 2011)

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

1,200

Conditions

Iron-deficiency

Interventions

Iron deficiency testingDIAGNOSTIC_TEST

Blood sample for complete iron status

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient, male or female, over the age of 18 * Patient in an oncology department (any type of tumor, any type of treatment, initiated or not) * Patient affiliated or beneficiary of a social security system * Patient with written consent Exclusion Criteria: * Protected patient: major under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision * Patient hospitalized without consent

Outcomes

Primary Outcomes

Blood iron status

ferritin, haemoglobin, transferrin saturation factor

Time frame: One day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.